Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Synguton May 29, 2015 6:50pm
200 Views
Post# 23779829

RE:RE:NEWS - Theralase increases revenues 2% in Q1 2015

RE:RE:NEWS - Theralase increases revenues 2% in Q1 2015I'm actually surprised the expenditures were that low! added to the TLT team were world renown doctors and researchers. The cost of research is not cheap folks! The marketing ramp up for the TLC-2000 and TLC-3000 is predictable and necessary. You can't expect to sit on the sidelines and hope someone notices. I expect the expenditures to grow in the coming quarters.

Hopefully, the TLC-2000 sales will to help offset some of the expenses. At the same time, we need to be wary of their cash position. I expect a pp announcement in the Fall as excitement builds with the upcoming trials.
Bullboard Posts